News News Details

Apexigen successfully listed on Nasdaq!

Date: 2022-08-01
Views: 500

Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of Nasdaq successfully and presented in stock code “APGN” this evening, August 1st, Beijing time. 


In July 2018, Efung Capital was one of the players of Apexigen's Series C financing.


Headquartered in San Carlos, CA, Apexigen is a clinical-stage biopharmaceutical company. It focuses on inventing the new generations of antibodies that target on cancer immunotherapies. The Corporation possesses a distinctive antibody drug development platform, APXiMAB, which is currently being developed for its core product-APX005M- additional with pre-clinical programs.


The development platform enables the firm and its partners to foster high quality antibodies against plentiful targets, even those that are difficult to develop into drugs using traditional antibody elaboration techniques. Among all antibodies, seven of them using APXiMAB have already entered the clinical phase.


The current major product of Apexigen Corporations, APX005M, is a tumor immunotherapy antibody targeting CD40, which is currently in multiple Phase II clinical trials for a variety of symptoms.


Pai Zhu, the managing partner of Efung Capital, mentioned that Apexigen Company had an experienced management team and a promising pipeline. In the light of that, APX005M was the leading player in the global drug development. As we acclaim its listing on Nasdaq, we hope that Apexigen will continue to innovate and develop more ground-breaking products.


In the future, Efung Capital will continue to conduct research such as cell therapy, gene treatment, immunotherapy, and other emerging investment tracks. At the same time, the firm will continue to invest in innovative medical technology, and promote the industrialization of biomedical technology.


Related News / Recommended news More
2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
2022 - 07 - 25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务